Our Therapy
Despite significant advances in cancer treatment, including the introduction of immunotherapy, hundreds of thousands of patients in the USA still die of aggressive cancer every year.
For some cancer types, immunotherapy has had limited success. The challenge is that, while cancer cells modify the function of both lymphoid and myeloid immune cells to avoid being killed, conventional immunotherapies activate only T lymphocytes - a subset of lymphoid cells.
Adecto is taking a new approach – we are developing a monoclonal antibody that reprograms lymphoid AND myeloid cells. It generates a potent anti-tumor immune response, killing cancer cells, including those resistant to conventional immunotherapy.
Our solution does not impact healthy cells and has no adverse effects in vivo.
To learn more contact us.